SCHEMBL305036

SCHEMBL305036

CCC(CC)OC(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.40
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
TSHR P16473 4/20 0.35
ALDH1A1 P00352 2/20 0.35
MMP1 P03956 2/20 0.34
MMP2 P08253 2/20 0.34
CA12 O43570 1/20 0.34
MMP8 P22894 1/20 0.34
CA9 Q16790 1/20 0.34
USP2 O75604 1/20 0.33
MMP3 P08254 1/20 0.33
MGAM O43451 2/20 0.32
GAA P10253 2/20 0.32
SI P14410 2/20 0.32
MGAM2 Q2M2H8 2/20 0.32
HSD17B10 Q99714 1/20 0.32
SOAT1 P35610 1/20 0.32
PRKCA P17252 1/20 0.32
PRKCD Q05655 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL180145 0.88 CTSK (0.38) CTSKCA1CA2TSHRALDH1A1
SCHEMBL10938384 0.87 MAPT (0.39) CTSKCA1CA2ALDH1A1MMP1
SCHEMBL8990510 0.85 CTSK (0.33) CTSKCA1CA2MMP1MMP2
SCHEMBL1469110 0.85 ACACB (0.40) CTSKCA1CA2PRKCAPRKCD
SCHEMBL31731146 0.84 CA1 (0.35) CTSKCA1CA2ALDH1A1MGAM
SCHEMBL5537588 0.84 CA1 (0.35) CTSKCA1CA2PRKCAPRKCD
Bicarbonate SCHEMBL3240516 0.83 CTSK (0.36) CTSKCA2ALDH1A1SOAT1PRKCA
SCHEMBL14185384 0.83 SOAT1 (0.43) CTSKALDH1A1SOAT1PRKCAPRKCD
SCHEMBL1470047 0.82 CA1 (0.34) CTSKCA1CA2TSHRALDH1A1
SCHEMBL1440094 0.79 ALDH1A1 (0.57) CTSKALDH1A1MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US claimed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US claimed
EP-2447264-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-05-02 EP claimed
US-7687490-B2 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2010-03-30 US claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
US-20040176350-A1 Carbapenem compound KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2004-09-09 US claimed
EP-1398314-A1 CARBAPENEM COMPOUND Kyoto Pharmaceutical Industries, Ltd. (JP) 2004-03-17 EP claimed
US-20220209301-A1 CARBONATE SOLVENTS FOR NON-AQUEOUS ELECTROLYTES FOR METAL AND METAL-ION BATTERIES SCE FRANCE (FR) 2022-06-30 US disclosed
EP-3956288-A1 CARBONATE SOLVENTS FOR NON-AQUEOUS ELECTROLYTES FOR METAL AND METAL-ION BATTERIES SCE France (FR) 2022-02-23 EP disclosed
WO-2020212872-A1 CARBONATE SOLVENTS FOR NON-AQUEOUS ELECTROLYTES FOR METAL AND METAL-ION BATTERIES SCE FRANCE (FR) 2020-10-22 WO disclosed
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS MEIJI SEIKA KAISHA (JP) 2016-06-02 US disclosed
US-9260375-B2 Metallo-β-lactamase inhibitors MEIJI SEIKA KAISHA, LTD. (JP) 2016-02-16 US disclosed
EP-2415875-B1 METHOD FOR IDENTIFICATION OF METALLO-[BETA]-LACTAMASE-PRODUCING BACTERIUM MEIJI SEIKA PHARMA CO LTD (JP) 2015-11-04 EP disclosed
US-20040176350-A1 Carbapenem compound KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2004-09-09 US disclosed
EP-1398314-A1 CARBAPENEM COMPOUND Kyoto Pharmaceutical Industries, Ltd. (JP) 2004-03-17 EP disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed
EP-0682023-B1 Imidazopyridine derivatives and process for preparing the same TANABE SEIYAKU CO (JP) 1997-02-12 EP disclosed
EP-0682023-A1 Imidazopyridine derivatives and process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 1995-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD CTSK 3012/4885CA1 2558/4885CA2 2546/4885
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM CTSK 3219/4885CA1 3160/4885CA2 1641/4885
US-20040176350-A1 Carbapenem compound ALPI, SI, OXA1L CTSK 2122/4885CA1 3950/4885CA2 3197/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 CTSK 2053/4885CA1 769/4885CA2 62/4885
US-20160151322-A1 METALLO-B-LACTAMASE INHIBITORS ME1, MGAM, MANBA CTSK 505/4885CA1 921/4885CA2 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.